AndrewAlanNierenbergMD

Thomas P. Hackett, MD, Endowed Chair in Psychiatry at MGH, Director, Dauten Family Center for Bipolar Treatment Innovation, Associate Director, Depression Clinical and Research Program, Co-director, Center for Clinical Research Education, Division of Clinical Research, Massachusetts General Hospital, Professor of Psychiatry, Harvard Medical School

Join to view full profile

Dr. Nierenberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nierenberg's full profile

Already have an account?

Office
50 Staniford St
Suite 580
Boston, MA 02114
Phone+1 617-724-0837

Fax+1 617-726-6768

Summary

Dr. Andrew Nierenberg is a psychiatrist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Albert Einstein College of Medicine of Yeshiva University and has been in practice 37 years. He is experienced in depression, bipolar disorders , and psychopharmacology. He has more than 600 publications and over 35000 citings.

Education & Training

NYU Grossman School of MedicineResidency, Psychiatry, 1980 - 1984
Albert Einstein College of MedicineClass of 1980

Certifications & Licensure

MA State Medical License 1986 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Drug Therapy to Treat Minor Depression Start of enrollment: 2003 Feb 01
Completed
Not Applicable
Memantine and Cognitive Dysfunction in Bipolar Disorder Start of enrollment: 2005 Nov 01
Completed
Phase 4
Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) Start of enrollment: 2008 May 01
Completed
Phase 2
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) Start of enrollment: 2008 Jul 01
Completed
Phase 2
Comparative Effectiveness Study for Bipolar Disorder Start of enrollment: 2010 Sep 01
Completed
Phase 4
Exploring Biomarkers for Depression Start of enrollment: 2011 Aug 01
Completed
Complex Dynamic Systems in Mood Disorders Start of enrollment: 2011 Nov 01
Completed
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine Start of enrollment: 2017 Aug 24
Terminated
Phase 4
Sequential Therapy for the Treatment of Severe Bipolar Depression. Start of enrollment: 2018 Jan 15
Completed
Phase 2
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder Start of enrollment: 2019 Dec 05
Recruiting
Early Phase 1
Healthy Mind Healthy You: A Study of Mindfulness Start of enrollment: 2019 Feb 27
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

1 citations
Sociodemographics and clinical factors associated with depression treatment outcomes in 65,741 first-time users of selective serotonin reuptake inhibitors: A Danish co...
Kazi Ishtiak-Ahmed, Kaj Sparle Christensen, Erik Lykke Mortensen, Andrew A Nierenberg, Christiane Gasse
Journal of Affective Disorders. 2024-12-15
Early antibiotic exposure and risk of psychiatric and neurocognitive outcomes: systematic review and meta-analysis.
Jessica Emily Green, Anna Wrobel, Emma Todd, Wolfgang Marx, Michael Berk
The British Journal of Psychiatry. 2024-12-11
Understanding the relationship between childhood abuse and affective symptoms in bipolar disorder: New insights from a network analysis.
Anna L Wrobel, Megan Turner, Olivia M Dean, Michael Berk, Louisa G Sylvia
Psychiatry Research. 2024-12-01

Journal Articles

Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research
Gustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect

Authored Content

Peroxisome Proliferator Activated Receptor Gamma Co-Activator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric DisordersJanuary 2018

Press Mentions

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression After GeneSight TestingApril 9th, 2024
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2022 Earnings Call TranscriptApril 5th, 2023
6 Ways to Manage Productivity When You Have Bipolar DisorderFebruary 19th, 2021
Join now to see all

Grant Support

Comparative Effectiveness Study For Bipolar DisorderAgency For Healthcare Research And Quality2010
Pharmacotherapy For Minor DepressionNational Institute Of Mental Health2001–2004
Course Of Treatment Resistant DepressionNational Center For Research Resources1996–1999
Course Of Treatment Resistant DepressionNational Institute Of Mental Health1993–1996
The Course Of Treatment Resistant DepressionNational Institute Of Mental Health1992
Course Of Treatment Resistant DepressionNational Institute Of Mental Health1992